Luthfi Adnan Muhammad, Pramaningtyas Miranti Dewi
Department of Physiology, Faculty of Medicine, Universitas Islam Indonesia, Sleman, Special Region of Yogyakarta, Indonesia.
Clin Exp Hepatol. 2022 Sep;8(3):171-177. doi: 10.5114/ceh.2022.118275. Epub 2022 Aug 4.
Seaweed is a food that is widely consumed by Asian people and has many health benefits, including lipid and glycemic reduction, but the effect of seaweed on non-alcoholic fatty liver disease (NAFLD) has not been widely discussed. This study aims to compare the effect of seaweed consumption on improving liver injury in NAFLD patients. The primary outcome is the change of liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and g-glutamyl transferase [GGT]), while the secondary outcome includes body weight, waist circumstance, body mass index (BMI), lipid profile, insulin level, and insulin sensitivity and any related metabolic indicators. There was significant liver improvement in the intervention group, but some parameters from secondary outcomes showed no significant effect. Further studies with larger and heterogeneous populations are still needed to confirm the effectiveness of seaweed supplementation in NAFLD patients.
海藻是一种被亚洲人广泛食用的食物,有许多健康益处,包括降低血脂和血糖,但海藻对非酒精性脂肪性肝病(NAFLD)的影响尚未得到广泛讨论。本研究旨在比较食用海藻对改善NAFLD患者肝损伤的效果。主要结局是肝酶(丙氨酸氨基转移酶[ALT]、天冬氨酸氨基转移酶[AST]、碱性磷酸酶[ALP]和γ-谷氨酰转移酶[GGT])的变化,而次要结局包括体重、腰围、体重指数(BMI)、血脂谱、胰岛素水平、胰岛素敏感性以及任何相关的代谢指标。干预组的肝脏有显著改善,但次要结局的一些参数未显示出显著效果。仍需要对更大规模且异质性的人群进行进一步研究,以证实海藻补充剂对NAFLD患者的有效性。